CorFlow Therapeutics
The first combined diagnostic and therapeutic medical device for improving microvascular obstructions after a heart attack.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €44.0m | Series B | |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2020 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (8 %) | 4 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
CorFlow Therapeutics AG is a Swiss-based medical device company that develops solutions for heart attack patients with microvascular obstruction (MVO). The company's flagship product is the CorFlow Controlled Flow Infusion System, a technology designed to diagnose and treat MVO in the catheterization laboratory.
CorFlow's business model revolves around the development and commercialization of its proprietary medical devices. The company targets cardiologists and healthcare institutions as its primary clients. By providing a novel approach to treating MVO, CorFlow aims to improve patient outcomes and reduce the economic burden of cardiovascular diseases. The company has secured significant funding from venture capital firms, which will be used to advance its clinical programs and prepare for market entry.
Keywords: medical devices, cardiovascular, microvascular obstruction, MVO, heart attack, cardiology, CorFlow Controlled Flow Infusion System, MOCA-II, cardiac care, diagnostics